EMA Authorised: Seebri Breezhaler (glycopyrronium bromide) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Seebri Breezhaler, containing glycopyrronium bromide, for the treatment of chronic obstructive pulmonary disease in the European Union (decision …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Seebri Breezhaler (glycopyrronium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Novartis Europharm Limited. Decision date: 23/01/2026